v3.26.1
SCHEDULE OF DISCONTINUED OPERATIONS (Details) - USD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Current assets      
Current assets related to discontinued operations $ 48,533   $ 67,863
Current liabilities      
Current liabilities related to discontinued operations 713,260   1,233,478
Net revenue 16,358  
Operating expenses      
Selling, general, and administrative expenses 255,442 2,311,402  
Research and development 163,779  
Depreciation and amortization [1] 430,378  
Total operating expenses 255,442 2,905,559  
Operating loss (239,084) (2,905,559)  
Other income (expense)      
Other income [2] 300,000  
Loss on disposal of property and equipment (1,258)  
Total other income (expense) 300,000 (1,258)  
Net income (loss) from discontinued operations 60,916 (2,906,817)  
Operating Activities:      
Depreciation and amortization [3],[4] 587,252 694,032  
Loss on disposal of property and equipment 10,932  
Share-based compensation 1,028,335 1,304,904  
Accounts receivable, net (1,709,332) 368,284  
Prepaid and other assets (166,162) (32,759)  
Accrued royalties and expenses (105,442) 67,224  
Accrued bonuses and commissions (3,120,078) (2,566,461)  
Supplemental noncash investing and financing activities:      
Non-monetary exchange to acquire intangible assets 2,084,278  
Tissue Health Plus [Member]      
Current assets      
Accounts receivable, net 31,200   16,200
Prepaids 17,333   51,663
Current assets related to discontinued operations 48,533   67,863
Current liabilities      
Accrued bonuses and commissions [5] 704,132   1,125,371
Accrued royalties and expenses 9,128   108,107
Current liabilities related to discontinued operations 713,260   $ 1,233,478
Operating Activities:      
Depreciation and amortization 430,378  
Loss on disposal of property and equipment 1,258  
Share-based compensation 129,408  
Accounts receivable, net (15,000)  
Prepaid and other assets 34,330 (214,147)  
Accrued royalties and expenses (98,979) (103,830)  
Accrued bonuses and commissions (421,239) (329,231)  
Supplemental noncash investing and financing activities:      
Non-monetary exchange to acquire intangible assets $ 2,084,278  
[1] Depreciation expense of $5,461 was reclassified as continuing operations in the three months ended March 31, 2025 and is therefore no longer reflected in discontinued operations.
[2] Other income relates to due diligence payments received to compensate the Company for costs incurred to maintain limited operations of certain software, technology and cloud related services while an interested party conducted its due diligence. In March 2026, the due diligence period ended and was not extended.
[3] Depreciation expense of $5,461 was reclassified as continuing operations in the three months ended March 31, 2025 and is therefore no longer reflected in discontinued operations.
[4] Depreciation expense of $5,461 was reclassified as continuing operations in the three months ended March 31, 2025 and is therefore no longer reflected in discontinued operations.
[5] Accrued bonuses and commissions is comprised of severance for terminated THP employees.